MarketPulse

EU approval

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi, Regeneron Win EU Nod for Dupixent in Young Children with Chronic Urticaria

Dupixent gains European approval for treating moderate-to-severe chronic spontaneous urticaria in children ages 2-11, expanding the drug's pediatric portfolio.
SNYREGNchronic spontaneous urticariaDupixent
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Rezurock Wins EU Approval for Chronic Graft-Versus-Host Disease

European Commission approves Sanofi's Rezurock for chronic GvHD treatment in patients 12+, based on 74% response rate from Phase 2 trials.
SNYorphan drugEU approval
The Motley FoolThe Motley Fool··Lee Samaha

Tesla Poised for April Momentum: Delivery Growth, Cybercab Ramp Could Shift Sentiment

Tesla stock faces potential April 2026 catalyst convergence: delivery growth, Cybercab production acceleration, and potential EU autonomous driving approval.
TSLAregulatory approvalrobotaxi
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Sarclisa Subcutaneous Formulation Wins CHMP Backing for EU Approval

Sanofi's isatuximab subcutaneous formulation gains European regulatory endorsement for multiple myeloma, offering patients first cancer treatment with portable injector option.
SNYmonoclonal antibodyclinical trials
The Motley FoolThe Motley Fool··Josh Kohn-Lindquist

ImmunityBio Gains 41% Following European Approval of Bladder Cancer Therapy

ImmunityBio shares surged 41% after Europe approved its bladder cancer therapy ANKTIVA, enabling commercialization across 30+ nations and opening significant revenue opportunities.
IBRXIOVAKRYSbiotechbladder cancer